[Congressional Record (Bound Edition), Volume 161 (2015), Part 8]
[Senate]
[Page 11727]
[From the U.S. Government Publishing Office, www.gpo.gov]




             ENSURING ACCESS TO CLINICAL TRIALS ACT OF 2015

  Mr. McCONNELL. Mr. President, I ask unanimous consent that the 
Finance Committee be discharged from further consideration of S. 139 
and the Senate proceed to its immediate consideration.
  The PRESIDING OFFICER. Without objection, it is so ordered.
  The clerk will report the bill by title.
  The legislative clerk read as follows:

       A bill (S. 139) to permanently allow an exclusion under the 
     Supplemental Security Income program and the Medicaid program 
     for compensation provided to individuals who participate in 
     clinical trials for rare diseases or conditions.

  There being no objection, the Senate proceeded to consider the bill.
  Mr. McCONNELL. Mr. President, I further ask unanimous consent that 
the bill be read a third time and passed, and the motion to reconsider 
be considered made and laid upon the table with no intervening action 
or debate.
  The PRESIDING OFFICER. Without objection, it is so ordered.
  The bill (S. 139) was ordered to be engrossed for a third reading, 
was read the third time, and passed, as follows:

                                 S. 139

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Ensuring Access to Clinical 
     Trials Act of 2015''.

     SEC. 2. ELIMINATION OF SUNSET PROVISION.

       Effective as if included in the enactment of the Improving 
     Access to Clinical Trials Act of 2009 (Public Law 111-255, 
     124 Stat. 2640), section 3 of that Act is amended by striking 
     subsection (e).

                          ____________________